GLIPIDIAB 5

GLIPIDIAB 5 is a clinically proven oral antidiabetic medication containing Glipizide 5 mg as its active ingredient. It belongs to the sulfonylurea class of drugs and is formulated to effectively manage Type 2 Diabetes Mellitus (T2DM) in adults. Manufactured by Steris Healthcare Pvt. Ltd., GLIPIDIAB 5 is designed to regulate blood sugar levels by stimulating insulin secretion from pancreatic beta cells, thereby helping patients maintain glycemic control and reduce diabetes-related complications.

Diabetes, a chronic metabolic disorder, occurs when the body either resists insulin or fails to produce enough of it. GLIPIDIAB 5 helps restore this balance by enhancing the body’s natural insulin production and improving its utilization. Its reliability, consistent bioavailability, and patient-friendly profile make it one of the most trusted medications for long-term diabetes management.

Composition

• Active Ingredient: Glipizide IP 5 mg

• Dosage Form: Film-coated Tablet

• Therapeutic Class: Oral Hypoglycemic Agent (Sulfonylurea Derivative)

Pharmacological Classification

Glipizide belongs to the second-generation sulfonylureas, which are more potent and safer than earlier generations. It works by acting directly on pancreatic beta cells to enhance insulin secretion. Unlike insulin injections, which provide external insulin, Glipizide stimulates the pancreas to produce more insulin naturally—making it an effective and convenient oral therapy for diabetes control.

Mechanism of Action

GLIPIDIAB 5 functions through a dual mechanism:

1. Pancreatic Action:

   • Glipizide binds to ATP-sensitive potassium channels (KATP) on the beta-cell membrane of the pancreas.

   • This causes depolarization of the membrane, leading to the opening of calcium channels and an influx of calcium ions.

   • Increased intracellular calcium stimulates insulin granule exocytosis, resulting in increased insulin secretion.

2. Extra-Pancreatic Action:

   • It enhances the sensitivity of peripheral tissues (muscle and fat) to insulin, promoting glucose uptake.

   • It may also slightly reduce hepatic glucose output, further aiding in blood glucose control.

This coordinated mechanism ensures balanced glucose utilization and prevents hyperglycemia effectively.

Uses of GLIPIDIAB 5

GLIPIDIAB 5 is primarily indicated for the management of Type 2 Diabetes Mellitus (non-insulin-dependent diabetes). It helps in:

1. Glycemic Control: Maintaining normal blood glucose levels in adult diabetics.

2. Prevention of Complications: Reduces the risk of diabetes-related complications such as neuropathy, nephropathy, and retinopathy.

3. Combination Therapy: Used alone (monotherapy) or in combination with Metformin, Pioglitazone, or other oral hypoglycemics when single-drug therapy fails to achieve target control.

4. Improvement of Energy and Metabolism: Promotes stable energy levels by optimizing carbohydrate metabolism.

Key Benefits of GLIPIDIAB 5

• Effective Blood Sugar Control: Rapid onset and sustained glucose-lowering effect.

• Enhanced Insulin Secretion: Improves pancreatic response to glucose.

• Convenient Oral Administration: Ideal for patients who prefer tablets over insulin injections.

• Improves Quality of Life: Reduces symptoms like frequent urination, fatigue, and excessive thirst.

• Flexible Therapy Option: Can be combined with other antidiabetic agents for better results.

• Well-Tolerated: Minimal side effects when used as prescribed.

• Affordable Long-Term Management: Cost-effective solution for chronic diabetes care.

Dosage and Administration

• Recommended Dose:
  The usual initial dose is 2.5 mg to 5 mg once daily, taken 30 minutes before breakfast.
  The dosage may be gradually increased based on the patient’s response, usually up to 20 mg per day, divided into one or two doses.

• Route of Administration: Oral

• Timing: Administer before meals to ensure optimal insulin release in response to food intake.

Note: Dosage must be individualized based on fasting blood glucose levels, HbA1c values, and physician assessment.

Precautions and Safety Advice

• Hypoglycemia Risk:
  Glipizide can cause low blood sugar, especially when meals are skipped, after strenuous exercise, or when combined with alcohol or other antidiabetics. Symptoms include sweating, shakiness, confusion, and palpitations. Immediate sugar intake (like glucose or candy) is recommended if this occurs.

• Kidney and Liver Impairment:
  Use with caution as metabolism and excretion may be altered.

• Diet and Exercise:
  Continue prescribed diet and physical activity alongside medication for optimal results.

• Pregnancy and Lactation:
  Should be used only if clearly needed and under medical supervision. Insulin may be preferred during pregnancy.

• Elderly Patients:
  Require dose adjustments due to higher sensitivity to hypoglycemic effects.

• Alcohol Consumption:
  Avoid alcohol as it may potentiate hypoglycemia or cause disulfiram-like reactions.

• Drug Interactions:
  Certain drugs (e.g., beta-blockers, antifungals, steroids) may alter Glipizide’s effects. Always inform the physician about concurrent medications.

Possible Side Effects

GLIPIDIAB 5 is generally well-tolerated, but some patients may experience mild, temporary effects such as:

• Hypoglycemia (low blood sugar)

• Nausea or vomiting

• Headache or dizziness

• Mild gastrointestinal upset (bloating, gas, or diarrhea)

• Fatigue or drowsiness

• Skin rash or itching (rare and usually mild)

Severe allergic reactions, liver dysfunction, or blood disorders are extremely rare but require immediate medical attention.

Overdose and Management

An overdose of Glipizide may cause severe hypoglycemia. Symptoms include confusion, sweating, tremors, blurred vision, and in extreme cases, unconsciousness.
Treatment involves:

• Immediate administration of oral glucose or intravenous dextrose in hospital settings.

• Continuous glucose monitoring until full recovery.

Storage Instructions

• Store below 30°C, in a cool and dry place.

• Protect from moisture and direct sunlight.

• Keep out of reach of children.

• Do not use tablets past the expiry date printed on the pack.

Clinical Evidence and Efficacy

Clinical studies have consistently demonstrated the efficacy of Glipizide in lowering fasting plasma glucose (FPG) and glycosylated hemoglobin (HbA1c) levels in Type 2 diabetics. Compared to other sulfonylureas, Glipizide has a faster onset of action, shorter half-life, and lower risk of prolonged hypoglycemia, making it suitable for both newly diagnosed and long-term diabetic patients.

In controlled trials, patients taking Glipizide showed:

• Significant reduction in HbA1c (by 1.5–2%).

• Better postprandial glucose control.

• Fewer episodes of hypoglycemia when used correctly.

• Improved pancreatic beta-cell responsiveness.

These findings support its role as a first-line oral therapy for effective diabetes management.

Why Choose GLIPIDIAB 5 by Steris Healthcare?

Steris Healthcare Pvt. Ltd. is committed to delivering high-quality, research-driven pharmaceuticals that improve patients’ lives. GLIPIDIAB 5 is formulated using advanced technology to ensure uniform potency, stability, and rapid absorption for consistent therapeutic results.

Key Highlights:

• GMP-certified manufacturing ensuring purity and reliability.

• Clinically validated formulation for Type 2 Diabetes control.

• Accurate dosing for safe and predictable results.

• Trusted by physicians for long-term diabetic management.

• Enhanced patient adherence due to once or twice-daily dosing.